2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-155106
    SMA4 98%
    SMA4 is a selective PKG1α activator with basal EC50 value of 29 μM. SMA4 facilitates phosphorylation of the known PKG1 substrate, vasodilator-stimulated phosphoprotein (VASP), and inhibits human pulmonary arterial smooth muscle cells (hPASMC) proliferation. SMA4 can be used for cardiovascular disease research.
    SMA4
  • HY-155297
    Nebidrazine 55248-23-2 98%
    Nebidrazine is a centrally-acting hypotensive agent compared to clonidine, demonstrating weaker cardiovascular effects in rats. It induces dose-dependent hypotension and bradycardia when administered intracerebroventricularly (i.c.v.), with significantly lower sedative potential than clonidine in conscious rats. Yohimbine attenuates the cardiovascular effects of both Nebidrazine and clonidine, suggesting involvement of central alpha-autoreceptors sensitive to yohimbine. Unlike clonidine, Nebidrazine does not affect peripheral alpha-adrenoceptors in pithed rats, indicating a selective central mechanism. Chemical sympathectomy reduces Nebidrazine's cardiovascular effects more than clonidine's, and metiamide diminishes responses to both drugs, implicating central histamine receptors. These findings highlight Nebidrazine's distinct pharmacological profile and potential therapeutic application in managing hypertension through central alpha-autoreceptor stimulation.
    Nebidrazine
  • HY-15551A
    E-4031 free base 113558-89-7 98%
    E-4031 free base is a selective hERG potassium channel blocker for use in class III anti-arrhythmic studies.
    E-4031 free base
  • HY-155737
    ET receptor antagonist 1 98%
    ET receptor antagonist 1 (compound 16h) is an orally active ET receptor antagonist (IC50=0.18 nM), which can be used for research in pulmonary arterial hypertension (PAH). ET receptor antagonist 1 attenuates monocrotaline (HY-N0750) induced PAH in rat model.
    ET receptor antagonist 1
  • HY-155738
    ET receptor antagonist 2 98%
    ET receptor antagonist 2 (compound 16j) is an orally active ET receptor antagonist (IC50=0.22 nM), which can be used for research in pulmonary arterial hypertension (PAH). ET receptor antagonist 2 attenuates monocrotaline (HY-N0750) induced PAH in rat model.
    ET receptor antagonist 2
  • HY-155739
    ET receptor antagonist 3 98%
    ET receptor antagonist 3 (compound 17d) is an orally active ET receptor antagonist (IC50=0.26 nM), which can be used for research in pulmonary arterial hypertension (PAH). ET receptor antagonist 3 attenuates monocrotaline (HY-N0750) induced PAH in rat model.
    ET receptor antagonist 3
  • HY-155988
    Sirtuin modulator 6 476633-98-4 98%
    Sirtuin modulator 6 (compound 262) increases the lifespan of a cell. Sirtuin modulator 6 can be used for study of diabetes, obesity, neurodegenerative diseases, cardiovascular disease, and so an extracted from patent WO2009064913A1.
    Sirtuin modulator 6
  • HY-156017
    5-HT6R antagonist 1 98%
    5-HT6R antagonist 1 (Comopund 8) is a 5-HT6R antagonist (Ki: 5 nM). 5-HT6R antagonist 1 inhibits platelet aggregation. 5-HT6R antagonist 1 has excellent metabolic stability. 5-HT6R antagonist 1 reverses MK-801 (HY-15084B)-induced memory impairments in rats. 5-HT6R antagonist 1 can be used for Alzheimer's disease (AD) research.
    5-HT6R antagonist 1
  • HY-156023
    Sirtuin modulator 7 863589-52-0 99.28%
    Sirtuin modulator 7 is a sirtuin-modulating compound which may increase the lifespan of a cell, and may be used for research of diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and flushing which would benefit from increased mitochondrial activity.
    Sirtuin modulator 7
  • HY-156101
    Latanoprost amide 919281-21-3 98%
    Latanoprost amide is a derivative of the F-prostaglandin (FP) receptor agonist Latanoprost (HY-B0577).
    Latanoprost amide
  • HY-156501
    BT101 sodium
    BT101 (sodium), a complementary aptamer, has been developed to specifically inhibit BT100 function. BT100, a aptamer, inhibits binding of von Willebrand factor (VWF) to platelet glycoprotein GPIb, preventing arterial thrombosis.
    BT101 sodium
  • HY-156536
    RXFP1 receptor agonist-1 2924619-64-5 98%
    RXFP1 receptor agonist-1 (Example 2 peak2) is a RXFP1 receptor agonist. RXFP1 receptor agonist-1 stimulates cAMP production in HEK293 cells stably expressing human RXFP1, with an EC50 value of 300 nM.
    RXFP1 receptor agonist-1
  • HY-156537
    RXFP1 receptor agonist-2 2924460-54-6 98%
    RXFP1 receptor agonist-2 (Example 124) is a RXFP1 receptor agonist. RXFP1 receptor agonist-2 stimulates cAMP production in HEK293 cells stably expressing human RXFP1, with an EC50 value of 1 nM.
    RXFP1 receptor agonist-2
  • HY-156539
    RXFP1 receptor agonist-4 2941376-76-5 98%
    RXFP1 receptor agonist-4 (Example 268) is a RXFP1 receptor agonist. RXFP1 receptor agonist-4 stimulates cAMP production in HEK293 cells stably expressing human RXFP1, with an EC50 value of 4.9 nM.
    RXFP1 receptor agonist-4
  • HY-156541
    RXFP1 receptor agonist-6 2941346-85-4 98%
    RXFP1 receptor agonist-6 (Example 7) is a RXFP1 receptor agonist. RXFP1 receptor agonist-6 stimulates cAMP production in HEK293 cells stably expressing human RXFP1, with an EC50 value of 12 nM.
    RXFP1 receptor agonist-6
  • HY-156542
    RXFP1 receptor agonist-7 2941484-13-3 98%
    RXFP1 receptor agonist-7 (Example 2) is a RXFP1 receptor agonist. RXFP1 receptor agonist-7 stimulates cAMP production in HEK293 cells stably expressing human RXFP1, with an EC50 value of 4.2 nM.
    RXFP1 receptor agonist-7
  • HY-156543
    RXFP1 receptor agonist-8 2941271-76-5 98%
    RXFP1 receptor agonist-8 (Example 2) is a RXFP1 receptor agonist. RXFP1 receptor agonist-8 stimulates cAMP production in HEK293 cells stably expressing human RXFP1, with an EC50 value of 1.8 nM.
    RXFP1 receptor agonist-8
  • HY-156635
    TIE-2/VEGFR-2 kinase-IN-3 433224-09-0 98%
    TIE-2/VEGFR-2 kinase-IN-3, benzimidazole, is a potent TIE-2 and VEGFR-2 tyrosine kinase receptors inhibitors with IC50 values of 6.9 nM and 3.5 nM, respectively. TIE-2/VEGFR-2 kinase-IN-3 can be used for the research of angiogenesis.
    TIE-2/VEGFR-2 kinase-IN-3
  • HY-156637
    TIE-2/VEGFR-2 kinase-IN-4 433224-29-4 98%
    TIE-2/VEGFR-2 kinase-IN-4, benzimidazole, is a potent TIE-2 and VEGFR-2 tyrosine kinase receptors inhibitors with IC50 values of 5.2 nM and 5.1 nM, respectively. TIE-2/VEGFR-2 kinase-IN-4 can be used for the research of angiogenesis.
    TIE-2/VEGFR-2 kinase-IN-4
  • HY-156638
    TIE-2/VEGFR-2 kinase-IN-5 1014407-83-0 98%
    TIE-2/VEGFR-2 kinase-IN-5 is an anti-angiogenic agent. TIE-2/VEGFR-2 kinase-IN-5 also is a potent TIE-2 and VEGFR-2 tyrosine kinase inhibitor with pIC50 values of 7.78 nM and 8.11 nM, respectively. TIE-2/VEGFR-2 kinase-IN-5 can be used for the research of angiogenesis.
    TIE-2/VEGFR-2 kinase-IN-5
Cat. No. Product Name / Synonyms Application Reactivity